Vaccines (Nov 2020)

Innate and Adaptive Immune Responses against <i>Bordetella pertussis</i> and <i>Pseudomonas aeruginosa</i> in a Murine Model of Mucosal Vaccination against Respiratory Infection

  • Catherine B. Blackwood,
  • Emel Sen-Kilic,
  • Dylan T. Boehm,
  • Jesse M. Hall,
  • Melinda E. Varney,
  • Ting Y. Wong,
  • Shelby D. Bradford,
  • Justin R. Bevere,
  • William T. Witt,
  • F. Heath Damron,
  • Mariette Barbier

DOI
https://doi.org/10.3390/vaccines8040647
Journal volume & issue
Vol. 8, no. 4
p. 647

Abstract

Read online

Whole cell vaccines are frequently the first generation of vaccines tested for pathogens and can inform the design of subsequent acellular or subunit vaccines. For respiratory pathogens, administration of vaccines at the mucosal surface can facilitate the generation of a localized mucosal immune response. Here, we examined the innate and vaccine-induced immune responses to infection by two respiratory pathogens: Bordetella pertussis and Pseudomonas aeruginosa. In a model of intranasal administration of whole cell vaccines (WCVs) with the adjuvant curdlan, we examined local and systemic immune responses following infection. These studies showed that intranasal vaccination with a WCV led to a reduction of the bacterial burden in the airways of animals infected with the respective pathogen. However, there were unique changes in the cytokines produced, cells recruited, and inflammation at the site of infection. Both mucosal vaccinations induced antibodies that bind the target pathogen, but linear regression and principal component analysis revealed that protection from these pathogens is not solely related to antibody titer. Protection from P. aeruginosa correlated to a reduction in lung weight, blood lymphocytes and neutrophils, and the cytokines IL-6, TNF-α, KC/GRO, and IL-10, and promotion of serum IgG antibodies and the cytokine IFN-γ in the lung. Protection from B. pertussis infection correlated strongly with increased anti-B-pertussis serum IgG antibodies. These findings reveal valuable correlates of protection for mucosal vaccination that can be used for further development of both B. pertussis and P. aeruginosa vaccines.

Keywords